Affinage

TAGLN2

Transgelin-2 · UniProt P37802

Length
199 aa
Mass
22.4 kDa
Annotated
2026-06-10
51 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TAGLN2 is an actin-binding protein that controls cortical actin architecture and acts as a signaling scaffold linking cytoskeletal remodeling to immune, developmental, and oncogenic programs (PMID:25869671, PMID:29615809). At the immunological synapse it stabilizes F-actin by competing with cofilin to block depolymerization, sustaining LFA-1 activation, T cell adhesion, spreading, and cytotoxic effector function (PMID:25869671); it physically associates with LFA-1 to potentiate inside-out integrin activation, an axis exploitable to enhance cytotoxic and CAR-T cell killing of tumor cells (PMID:30524895). Biochemically, TAGLN2 nucleates G-actin polymerization through its calponin homology domain and actin-binding loop under low-salt conditions and, under physiological conditions, blocks Arp2/3 binding to filaments to inhibit branched nucleation and promote filopodium-like protrusions (PMID:29615809). Its actin-regulatory activity is tuned by post-translational modification: PFTK1-mediated phosphorylation at S83/S163 reduces actin-binding affinity and relieves TAGLN2 suppression of cell invasion and motility (PMID:21577206), while K40 succinylation drives an interaction with TMSB4X that promotes angiogenesis and cytoskeletal remodeling in glioma (PMID:36131066). TAGLN2 is induced in macrophages by LPS via NF-κB and is required for Fc-receptor phagocytosis and host defense through PI3K/AKT and Ras-ERK signaling (PMID:28821818). Across multiple cancers, TAGLN2 acts as a pro-tumorigenic scaffold by binding partners including ARPC5 (MEK/ERK) (PMID:38744388), E-cadherin (trophoblast invasion) (PMID:35281112), ERK1/2 (MGMT-driven temozolomide resistance) (PMID:38992489), CXCR7 (TGF-β/Smad2) (PMID:41169389), and the AKT-YBX1 complex (cGAS-STING/ISG resistance) (PMID:39168971), and by promoting EMT and invasion through STAT3/ANXA2 and Rap1/PI3K/AKT axes (PMID:34466149, PMID:36222755).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2011 High

    Established TAGLN2 as a phosphoregulated effector downstream of a kinase, showing that its actin-binding activity is switchable and links to cancer cell invasion.

    Evidence Phosphosite mapping by 2D-PAGE/MS, S83/S163 mutagenesis, PFTK1 knockdown/overexpression, and epistasis in HCC cells

    PMID:21577206

    Open questions at the time
    • Structural basis of how phosphorylation reduces actin affinity not resolved
    • Whether other kinases target the same sites unknown
  2. 2014 Low

    Identified an upstream miRNA brake on TAGLN2 and linked its dosage to cardiomyocyte apoptosis, hinting at non-cancer roles.

    Evidence Dual-luciferase 3'-UTR reporter for miR-133a and TAGLN2 KO in hypoxic H9c2 cells

    PMID:25421410

    Open questions at the time
    • Limited mechanistic depth on TAGLN2 protein function itself
    • Caspase-8 axis link is correlative
  3. 2015 High

    Defined the core molecular mechanism: TAGLN2 stabilizes F-actin by competing with cofilin, connecting it to immunological synapse integrity and T cell function.

    Evidence TAGLN2 KO mouse T cells, in vitro cofilin competition assay, live-cell IS imaging, adhesion/cytotoxicity readouts

    PMID:25869671

    Open questions at the time
    • Stoichiometry of TAGLN2-cofilin competition on filaments not quantified
    • Regulation of TAGLN2 recruitment to the synapse unclear
  4. 2016 Medium

    Extended TAGLN2 function to viral biology, placing it downstream of HBx as a positive regulator of HBV replication.

    Evidence Gain/loss-of-function in HepG2 cells with HBV transcription/replication readouts and Tet-on HBx system

    PMID:27402267

    Open questions at the time
    • Direct molecular mechanism by which TAGLN2 enhances HBV transcription unknown
    • Single method per direction
  5. 2017 High

    Showed TAGLN2 is an LPS/NF-κB-induced effector required for macrophage phagocytosis and host defense, establishing an innate-immune role.

    Evidence TAGLN2 KO macrophages, opsonized-particle phagocytosis assays, PI3K/AKT and Ras-ERK pathway analysis, in vivo infection survival

    PMID:28821818

    Open questions at the time
    • Whether TAGLN2 acts directly at the phagocytic cup or via signaling not separated
    • Direct effectors linking TAGLN2 to PI3K/AKT not identified
  6. 2018 High

    Resolved the biochemical mechanism of actin regulation (nucleation vs. Arp2/3 inhibition) and defined a therapeutically actionable TAGLN2-actin-LFA-1 immunotherapy axis.

    Evidence In vitro polymerization assays with domain mutants, Arp2/3 binding assay, filopodia imaging (29615809); Co-IP and cell-permeable TG2P with cytotoxicity/tumor models (30524895)

    PMID:29615809 PMID:30524895

    Open questions at the time
    • High-resolution structure of TAGLN2-actin and TAGLN2-LFA-1 interfaces lacking
    • How salt conditions translate to physiological switching unclear
  7. 2021 Medium

    Embedded TAGLN2 in transcriptional networks and tumor signaling, showing both an in vivo developmental driver (klf6a) and a STAT3/ANXA2 oncogenic route.

    Evidence Zebrafish klf6a epistasis with EC rearrangement imaging (34319989); CRC gain/loss-of-function with STAT3 inhibitor rescue (34466149)

    PMID:34319989 PMID:34466149

    Open questions at the time
    • Direct vs. indirect TAGLN2-STAT3 link not established
    • Whether klf6a-tagln2 axis is conserved in mammals untested
  8. 2022 Medium

    Diversified the partner/PTM repertoire, identifying K40 succinylation (TMSB4X), direct E-cadherin binding, and Rap1/PI3K/AKT-mediated invasion across angiogenesis, trophoblast, and thyroid contexts.

    Evidence MS-identified K40succ with mimetic mutants and TMSB4X co-localization (36131066); Co-IP+MST for E-cadherin with trophoblast assays (35281112); proteomics and Rap1/PI3K/AKT rescue in PTC (36222755)

    PMID:35281112 PMID:36131066 PMID:36222755

    Open questions at the time
    • Enzyme controlling K40 succinylation not identified
    • Each partner shown by single lab without reciprocal cross-validation
  9. 2024 Medium

    Expanded TAGLN2 into a multi-pathway scaffold in cancer, binding ARPC5 (MEK/ERK), ERK1/2 (MGMT/TMZ resistance), and the AKT-YBX1 complex (cGAS-STING/ISG resistance).

    Evidence Co-IP/IF and ARPC5 epistasis with MEK inhibitor in pancreatic cancer (38744388); Co-IP/LC-MS/MS, ChIP-PCR and xenografts in GBM (38992489); Co-IP, ChIP and cGAS-STING readouts in gastric cancer (39168971)

    PMID:38744388 PMID:38992489 PMID:39168971

    Open questions at the time
    • Whether these interactions are direct or scaffolded via actin not dissected
    • Context-specificity of partner selection unexplained
  10. 2025 Medium

    Demonstrated TAGLN2 drives intercellular signaling (exosomal transfer, CXCR7/TGF-β/Smad2) and inflammatory ANXA2/NF-κB injury, broadening it from cell-autonomous to niche-level functions.

    Evidence Exosome delivery, ChIP and Co-IP for NRP1-SEMA4D-YAP (41824788); Co-IP/IF and CXCR7 rescue with p-Smad2 readout (41169389); TAGLN2 KO AP-liver injury model (40472315)

    PMID:40472315 PMID:41169389 PMID:41824788

    Open questions at the time
    • Mechanism of TAGLN2 sorting into exosomes unknown
    • Stoichiometry and structure of NRP1-SEMA4D ternary complex undefined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How TAGLN2 selects among its many signaling partners in a given cell type, and whether its scaffolding functions depend on or are separable from its actin-regulatory activity, remains unresolved.
  • No unifying model connecting actin regulation to partner-specific signaling
  • No structural data on the multiple interaction interfaces
  • Endogenous physiological vs. pathological context of each axis not delineated

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 3 GO:0060090 molecular adaptor activity 3
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 2 GO:0005856 cytoskeleton 2
Pathway
GO:0005856 cytoskeleton 2
Partners
ARPC5CXCR7E-CADHERINERK1/2LFA-1NRP1SEMA4DYBX1

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 TAGLN2 stabilizes cortical F-actin at the immunological synapse (IS) by competing with cofilin to block actin depolymerization, both in vitro and in vivo. TAGLN2 knockout reduced F-actin content and destabilized F-actin ring formation, resulting in decreased LFA-1 activation, cell adhesion, spreading, cytokine production, and cytotoxic effector function in T cells. TAGLN2 knockout mouse T cells, in vitro actin depolymerization competition assay with cofilin, live-cell imaging of IS F-actin ring, adhesion/spreading/cytokine/cytotoxicity assays The Journal of cell biology High 25869671
2018 TAGLN2 nucleates G-actin polymerization under low-salt conditions through its calponin homology domain and actin-binding loop, which mechanically connect two adjacent G-actin monomers mediating multimeric interactions. Under physiological salt conditions, TAGLN2 blocks Arp2/3 complex binding to actin filaments, thereby inhibiting branched actin nucleation and promoting filopodium-like membrane protrusions in HeLa and T cells. In vitro actin polymerization assays under low-salt and physiological conditions, domain deletion/mutation analysis (calponin homology domain and actin-binding loop), Arp2/3 complex binding assay, live-cell imaging of filopodia in HeLa and T cells Scientific reports High 29615809
2011 PFTK1 kinase phosphorylates TAGLN2 at serine residues S83 and S163, reducing its actin-binding affinity. In PFTK1-suppressed hepatocellular carcinoma (HCC) cells, unphosphorylated TAGLN2 shows strong actin-binding and inhibits actin cytoskeleton dynamics, cell invasion, and motility. Knockdown of TAGLN2 in PFTK1-suppressed cells overrides the inhibitory effect on cell invasion/motility, placing TAGLN2 downstream of PFTK1 in an oncogene-tumor suppressor axis. 2D-PAGE mass spectrometry to identify phosphorylated substrates, site-directed mutagenesis of S83 and S163, PFTK1 knockdown/overexpression, actin polymerization assay, cell invasion and motility assays, epistasis (double knockdown) Oncogene High 21577206
2017 TAGLN2 is induced in macrophages by LPS via the NF-κB pathway. TAGLN2-deficient macrophages show defective phagocytosis of IgM/IgG-opsonized red blood cells and bacteria, with down-regulation of PI3K/AKT and Ras-ERK signaling pathways involved in actin rearrangement. TAGLN2-/- mice show higher mortality after bacterial infection than wild-type littermates. TAGLN2 knockout macrophages (TAGLN2-/- mice), phagocytosis assays (IgM- and IgG-coated sheep RBCs and bacteria), PI3K/AKT and Ras-ERK pathway analysis, NF-κB pathway inhibition, in vivo bacterial infection survival assay Scientific reports High 28821818
2018 TAGLN2 is physically associated with LFA-1 and potentiates 'inside-out' activation of LFA-1 to enhance immunological synapse formation between T cells and tumor cells. A cell-permeable recombinant TAGLN2 (TG2P, fused with protein transduction domain) enhanced cytotoxic T cell killing of ICAM-1-positive tumor cells and reduced tumor growth in mice. The TAGLN2-actin-LFA-1 axis also enhanced CAR-T cell killing of Raji B-lymphoma cells. Co-immunoprecipitation (TAGLN2-LFA-1 interaction), recombinant protein transduction (TG2P), OTI TCR CD8+ T cell cytotoxicity assays against ICAM-1+/- tumor cells, in vivo tumor growth assay, CAR-T cell killing assay Oncoimmunology Medium 30524895
2022 Lysine-40 succinylation (K40succ) of TAGLN2 promotes glioma angiogenesis and tumor growth. A succinylation-mimetic mutant (TAGLN2-K40E) promotes angiogenesis, VE-cadherin expression, actin cytoskeleton remodeling, and tumor cell adhesion/metastasis in vitro and in vivo. TAGLN2 interacts with TMSB4X (co-localizing in nucleus and cytoplasm), and this interaction is dependent on WT TAGLN2 but not the non-succinylated K40A mutant. Inhibition of TMSB4X attenuates TAGLN2-K40succ-induced proliferation and migration. TMT labeling and LC-MS/MS to identify K40 succinylation, succinylation-mimetic (K40E) and non-succinylatable (K40R/K40A) mutants, in vitro angiogenesis assays, in vivo xenograft tumors, immunofluorescence co-localization of TAGLN2 and TMSB4X Cancer gene therapy Medium 36131066
2022 TAGLN2 binds directly to E-cadherin (shown by co-immunoprecipitation and microscale thermophoresis). Decreased TAGLN2 expression reduces cleavage of the E-cadherin extracellular domain, impairing trophoblast migration, invasion, and fusion, and reducing soluble E-cadherin levels that affect placental blood vessel formation. TAGLN2 overexpression (adenoviral) in pregnant mice induced a PE-like syndrome. Co-immunoprecipitation and microscale thermophoresis (TAGLN2-E-cadherin binding), TAGLN2 knockdown in trophoblast cell lines, migration/invasion/fusion assays, E-cadherin cleavage analysis, in vivo adenoviral TAGLN2 overexpression in pregnant mice Frontiers in cell and developmental biology Medium 35281112
2016 TAGLN2 positively regulates hepatitis B virus (HBV) transcription and replication: ectopic TAGLN2 expression in HepG2 cells enhanced HBV transcription and replication, while TAGLN2 knockdown had the opposite effect. The viral protein HBx induced TAGLN2 expression in a dose-dependent manner in a Tet-on HBx cell line. Ectopic expression and knockdown of TAGLN2 in HepG2 and HepG2.2.15 cells, HBV transcription/replication assays (qRT-PCR for HBc, HBs, HBx), Tet-on HBx inducible system Biochemical and biophysical research communications Medium 27402267
2021 In zebrafish, klf6a transcription factor directly drives tagln2 expression as a downstream target during caudal vein pruning. The klf6a-tagln2 axis regulates endothelial cell rearrangement (nucleus migration, junction remodeling, actin cytoskeleton dynamics) required for vessel pruning. Zebrafish genetic loss-of-function (klf6a disruption), epistasis placing tagln2 downstream of klf6a in vessel pruning, live imaging of EC rearrangement, actin cytoskeleton analysis in transgenic embryos PLoS genetics Medium 34319989
2024 TAGLN2 interacts with ERK1/2 (shown by Co-IP and LC-MS/MS). TAGLN2 knockdown decreases p-ERK1/2 nuclear expression, while overexpression increases it. TAGLN2 regulates MGMT expression downstream of ERK, contributing to temozolomide resistance. NF-κB regulates TAGLN2 expression (validated by ChIP-PCR). TAGLN2 also promotes proneural-to-mesenchymal transition in GBM. Co-immunoprecipitation, LC-MS/MS, TAGLN2 knockdown/overexpression in GBM cells, p-ERK1/2 nuclear localization analysis, MGMT expression assays, chromatin immunoprecipitation (ChIP-PCR) for NF-κB binding to TAGLN2 promoter, intracranial xenograft mouse models Cancer letters Medium 38992489
2021 TAGLN2 promotes colorectal cancer cell proliferation, invasion, migration, and EMT by activating STAT3 signaling through ANXA2. TAGLN2 knockdown suppresses STAT3 phosphorylation, and STAT3 inhibitor reverses the pro-tumorigenic effects of TAGLN2 overexpression. ANXA2 expression is positively associated with STAT3. TAGLN2 shRNA knockdown and overexpression in CRC cell lines, STAT3 phosphorylation western blot, STAT3 inhibitor rescue experiment, ANXA2-STAT3 association by western blot, proliferation/migration/invasion/EMT assays Oncology letters Medium 34466149
2022 TAGLN2 promotes invasion of papillary thyroid carcinoma cells via the Rap1/PI3K/AKT signaling pathway. Rescue experiments validated involvement of this pathway in TAGLN2-mediated invasion. Quantitative proteomics identified ITGB5, LAMC2, CRKL, vimentin, N-cadherin, and E-cadherin as downstream molecules. Gain- and loss-of-function in PTC cell lines (K1, TPC-1, BCPAP), gene expression profiling, quantitative proteomics, western blotting, Rap1/PI3K/AKT pathway rescue experiments, invasion/migration/angiogenesis assays Endocrine-related cancer Medium 36222755
2024 TAGLN2 upregulates resistance-signature interferon-stimulated genes (ISGs) in gastric cancer by enhancing YBX1-associated ssDNA aggregation and cGAS-STING pathway activation. TAGLN2 modulates YBX1 by recruiting c-Myc and SOX9 to the YBX1 promoter region and by directly interacting with AKT-YBX1, thereby enhancing YBX1 phosphorylation and nuclear translocation. Co-IP (TAGLN2-AKT-YBX1 interaction), ChIP assays (c-Myc and SOX9 at YBX1 promoter), ssDNA aggregation assays, cGAS-STING pathway analysis, ISG expression profiling, pharmacological inhibition (Fisetin, MK2206), xenograft tumor models Cell death & disease Medium 39168971
2025 TAGLN2 promotes activation of the ANXA2/NF-κB axis in Kupffer cells, contributing to inflammatory response and hepatocyte pyroptosis in acute pancreatitis-induced liver injury. TAGLN2 knockout reduced inflammatory cytokine levels, pyroptosis-related protein expression, and liver dysfunction markers. TAGLN2 knockout mice (cerulein-induced AP model), TAGLN2 knockdown in LPS-stimulated Kupffer cells, ANXA2/NF-κB pathway analysis, pyroptosis-related protein expression, cytokine measurement, liver injury markers (ALT, AST) Archivum immunologiae et therapiae experimentalis Medium 40472315
2024 TAGLN2 binds directly to ARPC5 (actin-related protein 2/3 complex subunit 5) as confirmed by co-immunoprecipitation and immunofluorescence co-localization. TAGLN2 promotes ARPC5 expression and activates the MEK/ERK signaling pathway; silencing ARPC5 reverses TAGLN2-driven proliferation, invasion, and metastasis of pancreatic cancer cells. Co-immunoprecipitation and immunofluorescence (TAGLN2-ARPC5 interaction), TAGLN2 overexpression/knockdown with ARPC5 silencing epistasis, MEK inhibitor (U0126), in vitro and in vivo tumor assays Cellular signalling Medium 38744388
2025 CXCR7 physically interacts with TAGLN2 in papillary thyroid carcinoma cells (shown by Co-IP and immunofluorescence co-localization). CXCR7 promotes PTC migration and invasion through TAGLN2 by activating the TGF-β/Smad2 signaling pathway. TAGLN2 knockdown decreases p-Smad2 levels, and CXCR7 re-introduction restores p-Smad2 in TAGLN2-silenced cells. Co-immunoprecipitation and immunofluorescence co-localization (CXCR7-TAGLN2), lentiviral cotransfection with TAGLN2 silencing and CXCR7 overexpression, p-Smad2/Smad2 western blot, migration assays in TPC-1 and BCPAP cells Frontiers in immunology Medium 41169389
2026 Tumor-derived exosomal TAGLN2 is delivered to endothelial cells where it transcriptionally upregulates NRP1 via c-Jun/SP1 and induces SEMA4D expression. TAGLN2 then interacts with both NRP1 and SEMA4D to form a stable cytoplasmic ternary complex that dually activates YAP (by disrupting NRP1-YAP binding and suppressing Hippo-mediated degradation), independently of the canonical SEMA4D-PlexinB1-RhoA/ROCK pathway. Exosome isolation and delivery experiments, ChIP (c-Jun/SP1 at NRP1 promoter), Co-IP (TAGLN2-NRP1-SEMA4D ternary complex), YAP localization/activity assays, in vivo tumor growth and lung metastasis models, combination drug treatment (cisplatin + MK2206) Advanced science Medium 41824788
2014 miR-133a directly binds the 3'-UTR of TAGLN2 mRNA (validated by dual-luciferase reporter assay) and suppresses TAGLN2 at both transcriptional and translational levels. TAGLN2 knockout modulates hypoxia-induced apoptosis in cardiomyocytes via the caspase-8 apoptotic pathway. Dual-luciferase reporter assay (miR-133a binding to TAGLN2 3'-UTR), TAGLN2 knockout in hypoxic H9c2 cells, caspase-8/-9/-3 and Bcl-2 protein expression analysis Molecular and cellular biochemistry Low 25421410
2018 TAGLN2 promotes meningioma cell proliferation, invasion, and survival while inhibiting apoptosis. TAGLN2 knockdown inhibited p-PI3K and p-AKT expression, while overexpression increased them, placing TAGLN2 upstream of the PI3K/AKT signaling pathway in meningioma cells. Lentiviral TAGLN2 knockdown and overexpression in CH157 meningioma cells, CCK8, colony formation, transwell invasion, flow cytometry apoptosis assays, p-PI3K and p-AKT western blot European review for medical and pharmacological sciences Low 29424888

Source papers

Stage 0 corpus · 51 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. British journal of cancer 247 21304530
2011 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 155 21378409
1995 Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. DNA research : an international journal for rapid publication of reports on genes and genomes 92 7788527
2015 TAGLN2 regulates T cell activation by stabilizing the actin cytoskeleton at the immunological synapse. The Journal of cell biology 82 25869671
2011 A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene 78 21577206
2018 miR-145-5p inhibits the proliferation and migration of bladder cancer cells by targeting TAGLN2. Oncology letters 65 30405771
2016 The tumor-suppressive function of miR-1 by targeting LASP1 and TAGLN2 in esophageal squamous cell carcinoma. Journal of gastroenterology and hepatology 57 26414725
2014 miR-133a mediates the hypoxia-induced apoptosis by inhibiting TAGLN2 expression in cardiac myocytes. Molecular and cellular biochemistry 48 25421410
2017 An Essential Role for TAGLN2 in Phagocytosis of Lipopolysaccharide-activated Macrophages. Scientific reports 41 28821818
2014 MiR-133b regulates the expression of the Actin protein TAGLN2 during oocyte growth and maturation: a potential target for infertility therapy. PloS one 37 24959893
2021 MicroRNA‑133b alleviates doxorubicin‑induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2. International journal of molecular medicine 33 33982775
2021 TAGLN2 promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of colorectal cancer cells by activating STAT3 signaling through ANXA2. Oncology letters 30 34466149
2018 MicroRNA-133b suppresses bladder cancer malignancy by targeting TAGLN2-mediated cell cycle. Journal of cellular physiology 24 30317571
2018 TAGLN2 polymerizes G-actin in a low ionic state but blocks Arp2/3-nucleated actin branching in physiological conditions. Scientific reports 23 29615809
2022 Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway. Bioengineered 19 35505656
2015 TAGLN2-mediated actin stabilization at the immunological synapse: implication for cytotoxic T cell control of target cells. BMB reports 19 26129675
2022 Lysine-40 succinylation of TAGLN2 induces glioma angiogenesis and tumor growth through regulating TMSB4X. Cancer gene therapy 18 36131066
2021 Quercetin Antagonizes Esophagus Cancer by Modulating miR-1-3p/TAGLN2 Pathway-Dependent Growth and Metastasis. Nutrition and cancer 17 34498538
2021 An Essential NRP1-Mediated Role for Tagln2 in Gastric Cancer Angiogenesis. Frontiers in oncology 16 34150622
2024 Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance. Cancer letters 15 38992489
2023 CircRNA ZKSCAN1 promotes lung adenocarcinoma progression by miR-185-5p/TAGLN2 axis. Thoracic cancer 15 37105934
2021 miR-133a-3p regulates the proliferation and apoptosis of intestinal epithelial cells by modulating the expression of TAGLN2. Experimental and therapeutic medicine 15 34149870
2022 TAGLN2-Regulated Trophoblast Migration, Invasion and Fusion are Impaired in Preeclampsia. Frontiers in cell and developmental biology 14 35281112
2022 TAGLN2 promotes papillary thyroid carcinoma invasion via the Rap1/PI3K/AKT axis. Endocrine-related cancer 14 36222755
2021 MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2. Cancer cell international 14 34530821
2024 TAGLN2 induces resistance signature ISGs by activating AKT-YBX1 signal with dual pathways and mediates the IFN-related DNA damage resistance in gastric cancer. Cell death & disease 13 39168971
2021 The blood flow-klf6a-tagln2 axis drives vessel pruning in zebrafish by regulating endothelial cell rearrangement and actin cytoskeleton dynamics. PLoS genetics 13 34319989
2018 Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1. Oncoimmunology 13 30524895
2022 Comparative proteomics identify HSP90A, STIP1 and TAGLN-2 in serum extracellular vesicles as potential circulating biomarkers for human adenomyosis. Experimental and therapeutic medicine 11 35495589
2018 Effect of TAGLN2 in the regulation of meningioma tumorigenesis and development. European review for medical and pharmacological sciences 10 29424888
2023 Single-cell RNA sequencing reveals the lineage of malignant epithelial cells and upregulation of TAGLN2 promotes peritoneal metastasis in gastric cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 9 37247132
2022 TAGLN2 Promotes the Proliferation, Migration, Invasion, and EMT of Clear Cell Renal Cell Carcinoma Through the PI3K/Akt Signaling Pathway. Biochemical genetics 9 36547768
2016 TAGLN2, a novel regulator involved in Hepatitis B virus transcription and replication. Biochemical and biophysical research communications 8 27402267
2024 Circular STAG2 RNA Modulates Bladder Cancer Progression via miR-145-5p/TAGLN2 and Is Considered as a Biomarker for Recurrence. Cancers 7 38473339
2019 [MicroRNA-133b suppresses cell proliferation and invasion of esophageal squamous cell carcinoma via downregulating TAGLN2 expression]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 7 30862136
2024 TAGLN2 targeted control of ARPC5-mediated activation of the MEK/ERK signaling pathway influences the proliferation, invasion, and metastasis of pancreatic cancer cells. Cellular signalling 6 38744388
2021 miR-133b targets tagln2 and functions in tilapia oogenesis. Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 5 34147671
2024 Down-regulation of TAGLN2 associated with the development of preeclampsia by effecting the Rap1 signaling pathway. Placenta 4 39602835
2025 TAGLN2 Exacerbates Acute Pancreatitis-Induced Liver Injury by Increasing Hepatocyte Pyroptosis via Kupffer Cells-Mediated Inflammatory Response. Archivum immunologiae et therapiae experimentalis 3 40472315
2025 TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma. Applied immunohistochemistry & molecular morphology : AIMM 2 40247723
2025 Isoliquiritigenin inhibits the activation of the ANXA2/STAT3 pathway by down-regulating TAGLN2, thereby alleviating alcoholic fatty liver. Biochemical pharmacology 2 40921221
2024 Metformin Radiosensitizing Effect on Hypoxic Oral Squamous Cell Carcinoma Cells by GAPDH and TAGLN2. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2 39160673
2020 Retracted Article: Overexpression of circ_0034642 contributes to hypoxia-induced glycolysis, cell proliferation, migration and invasion in gliomas by facilitating TAGLN2 expression via sponging miR-625-5p. RSC advances 2 35494452
2025 Decoding TAGLN2 in cancer: the molecular linchpin bridging actin remodeling, immune dysregulation and therapeutic challenges. International journal of biological macromolecules 1 40675291
2025 CXCR7-TAGLN2 protein complex regulates invasion and metastasis in papillary thyroid carcinoma: a potential therapeutic target. Frontiers in immunology 1 41169389
2025 Integrating Magnetic Bead-Based SELEX with In Silico Binding Analyses for the Identification of High-Affinity DNA Aptamers Targeting TAGLN2. ACS omega 1 41358073
2021 Retraction: Overexpression of circ_0034642 contributes to hypoxia-induced glycolysis, cell proliferation, migration and invasion in gliomas by facilitating TAGLN2 expression via sponging miR-625-5p. RSC advances 1 35427031
2026 Hsa_circ_PCNT sponges hsa-miR-133b to promote SHH medulloblastoma via TAGLN2. Cellular and molecular life sciences : CMLS 0 41483179
2026 Tumor-Derived Exosomal TAGLN2 Promotes Metastasis by Inducing Vascular Permeability and Angiogenesis via the NRP1/SEMA4D/YAP Axis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 0 41824788
2026 DNA Methylation-Mediated Regulation of TAGLN2 Expression Promotes Pulmonary Arterial Hypertension. Archives of medical research 0 42134034
2025 Exploration of upstream and downstream mechanisms of the TAGLN2 gene in pulmonary arterial hypertension. Medicine 0 41189171

Missed literature

Know a paper Affinage missed for TAGLN2? Flag it for the maintainers and the community.

No submissions yet.